Navigation Links
Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
Date:2/22/2012

SAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Citi 2012 Global Healthcare Conference in New York on Wednesday, February 29, 2012 at 11:00 a.m. ET / 8:00 a.m. PT. Kurt Gustafson, Chief Financial Officer, Halozyme Therapeutics, will provide a corporate overview.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
2. Halozyme Announces Proposed Public Offering of Common Stock
3. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
4. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
5. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
6. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
7. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
8. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
9. Halozyme Therapeutics to Present at Upcoming Financial Conferences
10. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
11. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und ... , Ziel der Zusammenarbeit ... Basis genomischer Daten aus Plasmaproben zur Steuerung von ... eingesetzt werden kann  Neuer Bluttest basiert ... Kit und soll auf Rotor-Gene Q, einer Automationsplattform ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
(Date:7/27/2014)... , July 27, 2014 /PRNewswire-iReach/ -- ... survey on Global and Chinese Vardenafil (CAS ... basic information of Vardenafil (CAS 224785-90-4) including ... report then explores global and China,s top ... product specification, capacity, production value, cost, gross ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 2Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 3Global and Chinese Vardenafil Industry (CAS 224785-90-4) 2019 Forecasts 4
... /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. ... traded biopharmaceutical company developing human vaccines for diseases ... infectious agents, announced today that Chuck Panozzo, founder ... joined the GeoVax Labs awareness campaign as an ...
... Boston Scientific Corporation (NYSE: BSX ) ... quality of life outcomes, based on one-year data from ... percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting ... hospital days during the first year after treatment compared ...
Cached Medicine Technology:Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 2Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 3Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 2SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 3SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 4SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease 5
(Date:7/28/2014)... Cuidado Casero , an organization of Medicare certified agencies ... Texas, New Mexico, New Jersey, Virginia, and Puerto Rico, was ... of PAM’s 2014 Gala. , North Texas PAMS is ... Texas chapter was created by a handful of Peruvian physicians ... care for the indigent in Peru. The chapter is developing ...
(Date:7/27/2014)... July 28, 2014 Recently, Wdsshop.de, a reliable ... new collection of fabulous prom dresses on its ... discounted prices, up to 58% off. , “We are pleased ... product line. They are specially created for those who are ... is great and vivid in style. I think our clients ...
(Date:7/27/2014)... provide shorter, more effective treatment options with fewer side ... C, even those most difficult to treat, according to ... Lancet . , Both studies focused on hepatitis C ... the USA, Europe, North Asia, Australia, and South America, ... Around 150 million people worldwide have chronic hepatitis C ...
(Date:7/27/2014)... Ticket Down is a reputable source ... in Inglewood, California on November 15th. This Australian boy band ... to hear songs from this amazing album at the concert. ... California at The Forum will be released for sale to the ... local time TicketDown.com. This popular secondary ticket exchange can also ...
(Date:7/27/2014)... Washington, DC (PRWEB) July 27, 2014 ... off as Latinos demonstrate their passion for protecting our ... community, particularly in the Southwest, will go on hiking ... presentations designed to show their support for permanently protecting ... is about sharing the Latino community’s perspective on the ...
Breaking Medicine News(10 mins):Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 2Health News:Latino Conservation Action Week Launches, Highlights Latinos’ Dedication to Protecting Our Environment 3
... 12 As the exclusive official,breaking news service ... 19-22, PR Newswire is featuring profiles of the ... Company: Defibtech, LLC, Booth Number: 16D18-11, ... LLC is a leading innovator in the field ...
... ForHealth Technologies, IntelliFill i.v. robot to ... reduces errors and ... ForHealth Technologies,Inc., a pioneer in medication error reduction and ... its robotic I.V. dose,preparation system, IntelliFill i.v.(TM), by the ...
... BERGEN, N.J., Nov. 12 The Vitamin Shoppe,announced ... Vice President,General Counsel and Corporate Secretary. Mr. Sander ... capacity, Mr. Sander will be responsible for,Legal Affairs, ... "As the Nation,s fastest growing specialty retailer of ...
... First member satisfaction survey shows health improvements, disease ... among valued benefits of plan -, SAN ANTONIO, Nov. ... 91 percent of members of Care Improvement Plus feel,their health ... satisfaction of the plan,s statewide membership. Of those who,feel health ...
... in the November issue of the Springer journal ... has been cut to levels substantially below the cost ... and clinics around the country are likely to discontinue ... to the test and jeopardizing those at risk for ...
... Donostia hospital in representation of Bioef are taking part in ... a portable device that will revolutionise the manner of controlling ... time needed for their detection from the current 24 hours ... to an increase in the number of control points. This ...
Cached Medicine News:Health News:Defibtech, LLC Exhibiting at MEDICA 2008 2Health News:Alegent Health System Automates I.V. Preparation to Enhance Patient Safety 2Health News:The Vitamin Shoppe Names James Sander Vice President, General Counsel and Corporate Secretary 2Health News:Texas Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Osteoporosis care at risk in the United States 2Health News:Design of system that will revolutionize control of influenza epidemics 2
... The Wound Care Manager ... for patient assessment and data ... care. This application was developed ... Wound Care along with the ...
... specifically for the Palm Organizers to ... rounds. It is intended to record ... that are requested by the senior ... round examinations and to record the ...
... patient tracking and billing. ... complete Handheld application, a ... complete CPT™ and ICD-9-CM ... AMA. Designed for any ...
In addition to the patient data OB-on-Call contains a comprehensive Medications list displaying related drugs by brand name, generic title, and usage description notes....
Medicine Products: